{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:28Z","timestamp":1761807688218,"version":"build-2065373602"},"reference-count":145,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s13311-013-0195-4","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T11:11:57Z","timestamp":1369221117000},"page":"400-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Experimental Models for Identifying Modifiers of Polyglutamine-Induced Aggregation and Neurodegeneration"],"prefix":"10.1016","volume":"10","author":[{"given":"Barbara","family":"Calamini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Kaltenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0195-4_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","article-title":"Trinucleotide repeat disorders","volume":"30","author":"Orr","year":"2007","journal-title":"Annu Rev Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11910-012-0277-4","article-title":"Therapy in Huntington's disease: where are we?","volume":"12","author":"Nance","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-013-0195-4_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0195-4_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainresbull.2011.07.016","article-title":"Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias","volume":"88","author":"Ingram","year":"2012","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-013-0195-4_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.06.005","article-title":"Rodent genetic models of Huntington disease","volume":"32","author":"Heng","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14728222.10.4.505","article-title":"Targeting protein aggregation in neurodegeneration\u2014lessons from polyglutamine disorders","volume":"10","author":"Weydt","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-013-0195-4_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.drudis.2009.02.006","article-title":"Small molecule drug discovery for Huntington's Disease","volume":"14","author":"Fecke","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1007\/s13311-013-0195-4_bib9","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/erm.2011.1","article-title":"RNA therapy for polyglutamine neurodegenerative diseases","volume":"14","author":"Watson","year":"2012","journal-title":"Expert Rev Mol Med"},{"key":"10.1007\/s13311-013-0195-4_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-013-0195-4_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.7.2.201","article-title":"Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases","volume":"7","author":"Steffan","year":"2003","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-013-0195-4_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/156652408784221298","article-title":"Molecular genetics and biomarkers of polyglutamine diseases","volume":"8","author":"Katsuno","year":"2008","journal-title":"Curr Mol Med"},{"key":"10.1007\/s13311-013-0195-4_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","article-title":"Development of biomarkers for Huntington's disease","volume":"10","author":"Weir","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0195-4_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0195-4_bib15","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/hmg\/ddr195","article-title":"HD CAG-correlated gene expression changes support a simple dominant gain of function","volume":"20","author":"Jacobsen","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1007\/s13311-013-0195-4_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1007\/s13311-013-0195-4_bib20","series-title":"Neurobiology of Huntington's Disease: applications to drug discovery","article-title":"High-throughput and high-content screening for Huntington's disease therapeutics","author":"Varma","year":"2011"},{"issue":"Suppl. 4","key":"10.1007\/s13311-013-0195-4_bib21","doi-asserted-by":"crossref","first-page":"16400","DOI":"10.1073\/pnas.182426599","article-title":"Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay","volume":"99","author":"Heiser","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","article-title":"Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib23","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1074\/jbc.275.14.10437","article-title":"Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening","volume":"275","author":"Nagai","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib24","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0896-6273(03)00697-4","article-title":"A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor","volume":"40","author":"Pollitt","year":"2003","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0195-4_bib26","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.110138997","article-title":"Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy","volume":"97","author":"Heiser","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jmb.2011.12.011","article-title":"Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting alpha-helix-rich oligomeric intermediates","volume":"415","author":"Mishra","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0195-4_bib28","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1074\/jbc.M111.252577","article-title":"Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein","volume":"287","author":"Nucifora","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib29","doi-asserted-by":"crossref","first-page":"26136","DOI":"10.1074\/jbc.M112.362764","article-title":"Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo","volume":"287","author":"Beam","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib30","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1523\/JNEUROSCI.0895-12.2012","article-title":"Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models","volume":"32","author":"Sontag","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1471-4159.2007.05032.x","article-title":"Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease","volume":"104","author":"Weiss","year":"2008","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0195-4_bib32","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.neurobiolaging.2010.12.012","article-title":"Lest we forget you--methylene blue\u2026","volume":"32","author":"Schirmer","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-013-0195-4_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","article-title":"Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice","volume":"36","author":"Li","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib34","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.febslet.2008.04.009","article-title":"ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation","volume":"582","author":"Shao","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-013-0195-4_bib35","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/MCB.00079-08","article-title":"Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation","volume":"28","author":"Shao","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-013-0195-4_bib36","doi-asserted-by":"crossref","first-page":"e56026","DOI":"10.1371\/journal.pone.0056026","article-title":"Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One."},{"key":"10.1007\/s13311-013-0195-4_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-391856-7.00041-X","article-title":"High-throughput screening in primary neurons","volume":"506","author":"Sharma","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1007\/s13311-013-0195-4_bib39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0195-4_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/hmg\/ddr500","article-title":"An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors","volume":"21","author":"Fuentealba","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.0408936102","article-title":"A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib42","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/cb100376q","article-title":"A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase","volume":"6","author":"Taylor","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1007\/s13311-013-0195-4_bib44","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1073\/pnas.1002924107","article-title":"SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis","volume":"107","author":"Luthi-Carter","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science."},{"key":"10.1007\/s13311-013-0195-4_bib46","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cbic.200900131","article-title":"Development of a method for the high-throughput quantification of cellular proteins","volume":"10","author":"Paganetti","year":"2009","journal-title":"Chembiochem"},{"key":"10.1007\/s13311-013-0195-4_bib47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ab.2010.11.044","article-title":"Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count","volume":"410","author":"Weiss","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1007\/s13311-013-0195-4_bib48","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1074\/jbc.M111.294801","article-title":"A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein","volume":"287","author":"Baldo","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.chembiol.2011.12.020","article-title":"TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease","volume":"19","author":"Baldo","year":"2012","journal-title":"Chem Biol"},{"key":"10.1007\/s13311-013-0195-4_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","article-title":"Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease","volume":"67","author":"Miller","year":"2010","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0195-4_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nchembio.763","article-title":"Small-molecule proteostasis regulators for protein conformational diseases","volume":"8","author":"Calamini","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1007\/s13311-013-0195-4_bib52","doi-asserted-by":"crossref","first-page":"e1000291","DOI":"10.1371\/journal.pbio.1000291","article-title":"Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease","volume":"8","author":"Neef","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1007\/s13311-013-0195-4_bib53","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1371\/journal.pgen.0030082","article-title":"Huntingtin interacting proteins are genetic modifiers of neurodegeneration","volume":"3","author":"Kaltenbach","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-013-0195-4_bib54","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/ncb1477","article-title":"The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions","volume":"8","author":"Tam","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-013-0195-4_bib55","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/ncb1478","article-title":"Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state","volume":"8","author":"Kitamura","year":"2006","journal-title":"Nat Cell Biol."},{"key":"10.1007\/s13311-013-0195-4_bib56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/187152710793237377","article-title":"Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms","volume":"9","author":"Pruss","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1007\/s13311-013-0195-4_bib57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1087057110373392","article-title":"Composite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions","volume":"15","author":"Kaltenbach","year":"2010","journal-title":"J Biomol Screen"},{"key":"10.1007\/s13311-013-0195-4_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2011.04.015","article-title":"The role of IkappaB kinase complex in the neurobiology of Huntington's disease","volume":"43","author":"Khoshnan","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib59","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138161208784480117","article-title":"A critical evaluation of adenosine A2A receptors as potentially \"druggable\" targets in Huntington's disease","volume":"14","author":"Popoli","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-013-0195-4_bib60","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.nbd.2011.03.017","article-title":"Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay","volume":"43","author":"Reinhart","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib61","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nchembio.467","article-title":"Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins","volume":"6","author":"Hoffstrom","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1007\/s13311-013-0195-4_bib62","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click chemistry: diverse chemical function from a few good reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1007\/s13311-013-0195-4_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0195-4_bib64","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib65","doi-asserted-by":"crossref","first-page":"e1003042","DOI":"10.1371\/journal.pgen.1003042","article-title":"A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease","volume":"8","author":"Miller","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-013-0195-4_bib66","doi-asserted-by":"crossref","first-page":"e23841","DOI":"10.1371\/journal.pone.0023841","article-title":"High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model","volume":"6","author":"Schulte","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0195-4_bib67","doi-asserted-by":"crossref","first-page":"e25999","DOI":"10.1371\/journal.pone.0025999","article-title":"A system for performing high throughput assays of synaptic function","volume":"6","author":"Hempel","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0195-4_bib68","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ncomms1518","article-title":"Synapse microarray identification of small molecules that enhance synaptogenesis","volume":"2","author":"Shi","year":"2011","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-013-0195-4_bib69","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tiv.2010.10.011","article-title":"Use of high content image analysis to detect chemical-induced changes in synaptogenesis in vitro","volume":"25","author":"Harrill","year":"2011","journal-title":"Toxicol In Vitro"},{"key":"10.1007\/s13311-013-0195-4_bib70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/1087057110388269","article-title":"Hydrogel tissue construct-based high-content compound screening","volume":"16","author":"Lam","year":"2011","journal-title":"J Biomol Screen"},{"key":"10.1007\/s13311-013-0195-4_bib71","doi-asserted-by":"crossref","first-page":"e49150","DOI":"10.1371\/journal.pone.0049150","article-title":"Induced tauopathy in a novel 3D-Culture model mediates neurodegenerative processes: a real-time study on biochips","volume":"7","author":"Seidel","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0195-4_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/157015907780077105","article-title":"Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics","volume":"5","author":"Cho","year":"2007","journal-title":"Curr Neuropharmacol"},{"key":"10.1007\/s13311-013-0195-4_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/mthe.2000.0235","article-title":"Gene transfer methods for CNS organotypic cultures: a comparison of three nonviral methods","volume":"3","author":"Murphy","year":"2001","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0195-4_bib74","article-title":"Neuronal transfection using particle-mediated gene transfer","author":"Lo","year":"2001","journal-title":"Curr Protoc Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrn2809","article-title":"Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?","volume":"11","author":"Khurana","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1385\/NMM:4:1-2:133","article-title":"Making yeast tremble: yeast models as tools to study neurodegenerative disorders","volume":"4","author":"Sherman","year":"2003","journal-title":"Neuromolecular Med"},{"key":"10.1007\/s13311-013-0195-4_bib77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-0-387-39975-1_15","article-title":"The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging","volume":"594","author":"Brignull","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1007\/s13311-013-0195-4_bib78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.genet.39.110304.095804","article-title":"Drosophila as a model for human neurodegenerative disease","volume":"39","author":"Bilen","year":"2005","journal-title":"Annu Rev Genet"},{"key":"10.1007\/s13311-013-0195-4_bib79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1073\/pnas.96.1.179","article-title":"Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron","volume":"96","author":"Faber","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib80","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1371\/journal.pone.0000504","article-title":"Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans","volume":"2","author":"Voisine","year":"2007","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0195-4_bib81","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.chembiol.2011.04.012","article-title":"Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment","volume":"18","author":"Wu","year":"2011","journal-title":"Chem Biol"},{"key":"10.1007\/s13311-013-0195-4_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrd2757","article-title":"Transient receptor potential channels: targeting pain at the source","volume":"8","author":"Patapoutian","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0195-4_bib83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.00021.2006","article-title":"Transient receptor potential cation channels in disease","volume":"87","author":"Nilius","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1007\/s13311-013-0195-4_bib84","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.1090389","article-title":"Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein","volume":"302","author":"Willingham","year":"2003","journal-title":"Science"},{"key":"10.1007\/s13311-013-0195-4_bib85","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","article-title":"A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease","volume":"37","author":"Giorgini","year":"2005","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0195-4_bib86","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cell.2011.12.032","article-title":"Spt4 is selectively required for transcription of extended trinucleotide repeats","volume":"148","author":"Liu","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib87","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1093\/hmg\/ddg271","article-title":"Fly models of Huntington's disease","volume":"12","author":"Marsh","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib88","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/138161212799315894","article-title":"Drosophila models of proteinopathies: the little fly that could","volume":"18","author":"Rincon-Limas","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-013-0195-4_bib89","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/emmm.200900051","article-title":"Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms","volume":"1","author":"van Ham","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1007\/s13311-013-0195-4_bib90","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.287.5459.1837","article-title":"Genetic suppression of polyglutamine toxicity in Drosophila","volume":"287","author":"Kazemi-Esfarjani","year":"2000","journal-title":"Science"},{"key":"10.1007\/s13311-013-0195-4_bib91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/35040584","article-title":"Identification of genes that modify ataxin-1-induced neurodegeneration","volume":"408","author":"Fernandez-Funez","year":"2000","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0195-4_bib92","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1371\/journal.pgen.0030177","article-title":"Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila","volume":"3","author":"Bilen","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-013-0195-4_bib93","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1534\/genetics.111.133710","article-title":"Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model","volume":"190","author":"Weiss","year":"2012","journal-title":"Genetics"},{"key":"10.1007\/s13311-013-0195-4_bib94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0195-4_bib95","doi-asserted-by":"crossref","first-page":"17131","DOI":"10.1073\/pnas.262544899","article-title":"Glutamine\/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity","volume":"99","author":"Faber","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib96","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1523\/JNEUROSCI.3344-05.2006","article-title":"Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity","volume":"26","author":"Bates","year":"2006","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib97","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","article-title":"CREB-binding protein sequestration by expanded polyglutamine","volume":"9","author":"McCampbell","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddg002","article-title":"Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein","volume":"12","author":"Jiang","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib99","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1073\/pnas.231476398","article-title":"Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death","volume":"98","author":"Parker","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng1534","article-title":"Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons","volume":"37","author":"Parker","year":"2005","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0195-4_bib101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2164-13-91","article-title":"Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons","volume":"13","author":"Lejeune","year":"2012","journal-title":"BMC Genomics"},{"key":"10.1007\/s13311-013-0195-4_bib102","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1073\/pnas.0307697101","article-title":"Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation","volume":"101","author":"Nollen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib103","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.molcel.2006.08.017","article-title":"Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers","volume":"23","author":"Behrends","year":"2006","journal-title":"Mol Cell"},{"key":"10.1007\/s13311-013-0195-4_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1255","article-title":"Modifiers of mutant huntingtin aggregation: functional conservation of C. elegans-modifiers of polyglutamine aggregation","volume":"3","author":"Teuling","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1007\/s13311-013-0195-4_bib105","doi-asserted-by":"crossref","first-page":"e1002438","DOI":"10.1371\/journal.pgen.1002438","article-title":"A genetic screening strategy identifies novel regulators of the proteostasis network","volume":"7","author":"Silva","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-013-0195-4_bib106","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","article-title":"Biological and chemical approaches to diseases of proteostasis deficiency","volume":"78","author":"Powers","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1007\/s13311-013-0195-4_bib107","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"10.1007\/s13311-013-0195-4_bib108","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/hmg\/7.9.1463","article-title":"Huntingtin interacts with a family of WW domain proteins","volume":"7","author":"Faber","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","article-title":"The hunt for huntingtin function: interaction partners tell many different stories","volume":"28","author":"Harjes","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1007\/s13311-013-0195-4_bib110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of Huntington's disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet"},{"key":"10.1007\/s13311-013-0195-4_bib111","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molcel.2004.09.016","article-title":"A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease","volume":"15","author":"Goehler","year":"2004","journal-title":"Mol Cell"},{"key":"10.1007\/s13311-013-0195-4_bib112","doi-asserted-by":"crossref","first-page":"21599","DOI":"10.1074\/jbc.M112.359307","article-title":"Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis","volume":"287","author":"Culver","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.05.024","article-title":"Network organization of the huntingtin proteomic interactome in mammalian brain","volume":"75","author":"Shirasaki","year":"2012","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0195-4_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neulet.2007.11.018","article-title":"14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein","volume":"431","author":"Omi","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-013-0195-4_bib115","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2006.03.032","article-title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration","volume":"125","author":"Lim","year":"2006","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0195-4_bib117","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0195-4_bib118","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0195-4_bib119","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib120","doi-asserted-by":"crossref","first-page":"E290","DOI":"10.1097\/01.BRS.0000087093.89889.0A","article-title":"Management of the cervical esophagus and hypofarinx perforations complicating anterior cervical spine surgery","volume":"28","author":"Orlando","year":"2003","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1007\/s13311-013-0195-4_bib121","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0195-4_bib122","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0195-4_bib123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2010.05.007","article-title":"Chaperone networks: tipping the balance in protein folding diseases","volume":"40","author":"Voisine","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib124","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/hmg\/ddm315","article-title":"Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases","volume":"17","author":"Branco","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0195-4_bib125","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.drudis.2012.06.017","article-title":"Targeting mutant huntingtin for the development of disease-modifying therapy","volume":"17","author":"Appl","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1007\/s13311-013-0195-4_bib126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1007\/s13311-013-0195-4_bib127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.gde.2012.07.004","article-title":"Human disease modeling with induced pluripotent stem cells","volume":"22","author":"Trounson","year":"2012","journal-title":"Curr Opin Genet Dev"},{"key":"10.1007\/s13311-013-0195-4_bib128","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","article-title":"Disease-specific induced pluripotent stem cells","volume":"134","author":"Park","year":"2008","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0195-4_bib129","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrd3577","article-title":"Induced pluripotent stem cells\u2013opportunities for disease modelling and drug discovery","volume":"10","author":"Grskovic","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0195-4_bib130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/092986710790514480","article-title":"Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery","volume":"17","author":"Gunaseeli","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1007\/s13311-013-0195-4_bib131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s13311-011-0075-8","article-title":"Cellular therapy and induced neuronal replacement for Huntington's disease","volume":"8","author":"Benraiss","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-013-0195-4_bib132","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mcn.2012.03.011","article-title":"Multiple phenotypes in Huntington disease mouse neural stem cells","volume":"50","author":"Ritch","year":"2012","journal-title":"Mol Cell Neurosci"},{"key":"10.1007\/s13311-013-0195-4_bib133","first-page":"160","article-title":"Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death","volume":"50C","author":"Conforti","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1193","article-title":"Characterization of human Huntington's disease cell model from induced pluripotent stem cells","volume":"2","author":"Zhang","year":"2010","journal-title":"PLoS Curr"},{"key":"10.1007\/s13311-013-0195-4_bib135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-5-17","article-title":"Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells","volume":"5","author":"Juopperi","year":"2012","journal-title":"Mol Brain"},{"key":"10.1007\/s13311-013-0195-4_bib136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BJ20111495","article-title":"Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient","volume":"446","author":"Chae","year":"2012","journal-title":"Biochem J"},{"key":"10.1007\/s13311-013-0195-4_bib137","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","article-title":"Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells","volume":"11","author":"An Mahru","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1007\/s13311-013-0195-4_bib138","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","article-title":"Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes","volume":"11","author":"HD iPSC Consortium","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1007\/s13311-013-0195-4_bib139","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2011.12.042","article-title":"The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity","volume":"46","author":"Camnasio","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0195-4_bib140","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-013-0195-4_bib141","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.gt.3302664","article-title":"RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases","volume":"13","author":"Denovan-Wright","year":"2006","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-013-0195-4_bib142","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-013-0195-4_bib143","first-page":"275","article-title":"Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system","volume":"351","author":"Pulak","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1007\/s13311-013-0195-4_bib144","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nmeth.1984","article-title":"An image analysis toolbox for high-throughput C. elegans assays","volume":"9","author":"Wahlby","year":"2012","journal-title":"Nat Methods"},{"key":"10.1007\/s13311-013-0195-4_bib145","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/hmg\/ddh214","article-title":"Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases","volume":"13","author":"Ghosh","year":"2004","journal-title":"Hum Mol Genet"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0195-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301231X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301231X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0195-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:53Z","timestamp":1761807113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301231X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":145,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S187874792301231X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0195-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental Models for Identifying Modifiers of Polyglutamine-Induced Aggregation and Neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0195-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}